SCHEMBL121322

SCHEMBL121322

COC(=O)c1ccc(S(=O)(=O)Nc2ncc(Br)cc2Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 3/20 0.47
FLT1 P17948 1/20 0.47
FLT4 P35916 1/20 0.47
KDR P35968 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 4/20 0.45
TSHR P16473 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
ALOX15 P16050 1/20 0.45
HTT P42858 1/20 0.45
CYP2C9 P11712 3/20 0.44
NHERF1 O14745 1/20 0.44
S100A9 P06702 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 4/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL120256 0.89 MEN1 (0.54) CCR4FLT1FLT4KDRMEN1
SCHEMBL118688 0.88 FLT1 (0.55) CCR4FLT1FLT4KDRMEN1
SCHEMBL119695 0.83 MEN1 (0.71) MEN1KMT2ATDP1ALDH1A1SMN1; SMN2
SCHEMBL119346 0.80 CYP2C9 (0.51) CCR4FLT1FLT4KDRMEN1
SCHEMBL118204 0.79 TSHR (0.53) FLT1FLT4KDRKMT2AALDH1A1
SCHEMBL117883 0.76 MEN1 (0.53) CCR4MEN1KMT2ATDP1ALDH1A1
SCHEMBL3160292 0.74 SCN3A (0.52) FLT1FLT4KDRKMT2AALDH1A1
SCHEMBL118604 0.72 MEN1 (0.54) MEN1KMT2ATDP1ALDH1A1TSHR
SCHEMBL17340511 0.72 ALDH1A1 (0.63) FLT1FLT4KDRKMT2ATDP1
SCHEMBL14721215 0.72 NPSR1 (0.41) ALDH1A1TSHRSMN1; SMN2HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 CCR4 4776/4885FLT1 3602/4885FLT4 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.